Background information

Porcine Respiratory Disease Syndrome (PRDS) is a syndrome caused by various respiratory infections. This disease not only leads to direct mortality in affected pigs but, more severely, results in a 5%-25% decline in feed utilization efficiency, a 5%-25% reduction in weight gain rate, and a delay of 15–20 days in market age. Additionally, it causes prolonged carriage of multiple pathogens,
significantly impairing the economic profitability of the swine industry.

Porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyopneumoniae) are recognized as the primary clinical pathogens responsible for porcine reproductive and developmental disease (PRDC), while vaccination serves as a critical measure for controlling infections caused by PCV2 and M. hyopneumoniae.
The use of a combined inactivated vaccine against PCV2 and M. hyopneumoniae can reduce post-weaning morbidity and mortality rates in piglets, enhance daily weight gain, shorten market age, and significantly lower breeding costs.

Product Features of Yuanzhiqing

The use of whole-virus and whole-bacterial inactivated antigens demonstrates definitive immunogenic efficacy.

Using inactivated antigens ensures safety and stability, eliminating concerns about re-virulence.
Complete inactivation of both the virus and bacteria preserves all protective antigenic determinants, guaranteeing reliable immunogenic efficacy

Employing High-Density Culture and Chromatographic Purification Techniques to Enhance Antigen Content and Purity.

The porcine circovirus type 2 antigen is produced using high-density culture of cloned PK-B1 cells, purified by ultrafiltration and chromatography, with an antigen purity of no less than 90% and a concentration of no less than 1x10^7.0TCID₅₀/head.
The Mycoplasma hyopneumoniae antigen is produced using Nanong High-Tech's patented culture medium and high-density fermentation process, with an antigen content of no less than 8x10⁸CCU per dose.

The Use of a Novel Water-Based Adjuvant Significantly Enhances Vaccine Efficacy and Safety.

The vaccine employs a novel water-soluble sustained-release adjuvant to synergistically enhance the immunogenic effects of both antigens, with a protection duration of no less than 4 months. Characterized by low viscosity, it is easy to administer without leaving residual deposits at the injection site, significantly reducing stress-related risks.

The Antigen of Porcine Circovirus Type 2 Exhibits a Synergistic Effect With the Antigen of Mycoplasma Pneumoniae in Pigs.

The full viral antigen of Porcine circovirus type 2 exhibits synergistic effects with the antigen of Mycoplasma hyopneumoniae; compared to monovalent vaccines, combined vaccination induces higher antibody levels.

Comparative Study Between Round Branch Qing and Single Seedlings

The Vaccine Offers Excellent Cost-Effectiveness and Significantly Enhances Production Efficiency in Pig Farms.

·Rapid and sustained production of effective antibodies against Porcine Circovirus type 2 following immunization
·Effectively reduces pulmonary lesions caused by Mycoplasma hyopneumoniae
·Reduce the incidence of disease and mortality rate in piglets, improve daily weight gain, and shorten the market-ready age.
·Reduce the likelihood of secondary infections caused by other pathogens and lower the incidence of epidemics. 

Dynamics of PCV2 antibody levels after immunization with Porcine Circular Virus (PCV)

Use of Yuanzhiqing

Immunization method: Intramuscular injection in the neck, 2 mL per head.
The first dose should be administered to piglets aged 14–21 days, followed by a booster dose at the same dosage two weeks later.
Precautions: To be used exclusively for vaccination of healthy pigs; the vaccine must not be frozen and should be protected from high temperatures or direct sunlight; restore the vaccine to room temperature before use and shake thoroughly; the vaccine should be consumed immediately after opening, with any remaining vaccine, vials, or syringes requiring proper disposal; standard aseptic techniques must be followed during administration.
Specifications: 20 ml/bottle, 100 ml/bottle.